<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="27584,30834">Aldosterone</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> are reported to have beneficial effects on diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> by effective blocking of the renin-angiotensin-<z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> system </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the renoprotective effect of the selective <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> receptor blocker <z:chebi fb="0" ids="31547">eplerenone</z:chebi>, the <z:chebi fb="0" ids="35457">angiotensin converting enzyme inhibitor</z:chebi> <z:chebi fb="0" ids="43755">lisinopril</z:chebi>, and combined <z:chebi fb="0" ids="31547">eplerenone</z:chebi> and <z:chebi fb="0" ids="43755">lisinopril</z:chebi> treatment in type 2 diabetic rats </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: ANIMALS WERE DIVIDED INTO SIX GROUPS AS FOLLOWS: Otsuka Long-Evans Tokushima Fatty (OLETF) rat control, OLETF rats treated with a low dose of <z:chebi fb="0" ids="31547">eplerenone</z:chebi> (50 mg/kg/day), OLETF rats treated with a high dose of <z:chebi fb="0" ids="31547">eplerenone</z:chebi> (200 mg/kg/day), OLETF rats treated with <z:chebi fb="0" ids="43755">lisinopril</z:chebi> (10 mg/kg/day), OLETF rats treated with a combination of both drugs (<z:chebi fb="0" ids="31547">eplerenone</z:chebi> 200 mg/kg/day and <z:chebi fb="0" ids="43755">lisinopril</z:chebi> 10 mg/kg/day), and <z:mp ids='MP_0001261'>obese</z:mp> non-diabetic Long-Evans Tokushima Otsuka rats for 26 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Urinary albumin excretion was significantly lower in the <z:chebi fb="0" ids="43755">lisinopril</z:chebi> group, but not in the <z:chebi fb="0" ids="31547">eplerenone</z:chebi> group </plain></SENT>
<SENT sid="4" pm="."><plain>Urinary albumin excretion was decreased in the combination group than in the <z:chebi fb="0" ids="43755">lisinopril</z:chebi> group </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000096'>Glomerulosclerosis</z:hpo> and renal expression of type I and type IV collagen, plasminogen activator inhibitor-1, transforming growth factor-Î²1, connective tissue growth factor, and fibronectin <z:chebi fb="2" ids="33699">mRNA</z:chebi> were markedly decreased in the <z:chebi fb="0" ids="43755">lisinopril</z:chebi>, <z:chebi fb="0" ids="31547">eplerenone</z:chebi>, and combination groups </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="31547">Eplerenone</z:chebi> and <z:chebi fb="0" ids="43755">lisinopril</z:chebi> combination showed additional benefits on type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> compared to monotherapy of each drug </plain></SENT>
</text></document>